Clinical Trial - COPD - Astegolimab Open Label Extension - Roche
2024年2月20日 · Trial Summary. The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Clinical trial for Chronic Obstructive Pulmonary Disease (C... - Roche
2024年2月20日 · Astegolimab is an experimental drug, meaning health authorities have not approved astegolimab for treating COPD. In this clinical trial, researchers will assess if people with COPD have fewer moderate or severe COPD exacerbations when astegolimab (at one of two doses) is added to their standard COPD treatment.
罗氏 ST2 单抗国内启动 III 期临床，瞄准百亿 COPD 市场！
9 月 27 日，据 Insight 数据库显示，罗氏 Astegolimab 国内启动 III 期临床 ARNASA 研究，针对慢性阻塞性肺疾病（COPD）（登记号：CTR20233027）。. 这也是国内首次启动的临床试验。.
Clinical Trial – Chronic Obstructive Pulmonary Disease – Ef... - Roche
2024年2月20日 · This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
Astegolimab, an anti-ST2, in chronic obstructive pulmonary …
2022年3月24日 · In patients with moderate-to-very severe COPD and a history of frequent exacerbations, treatment with astegolimab, a novel anti-ST2 monoclonal antibody, did not significantly reduce exacerbation rate over 48 weeks compared with placebo.
Astegolimab is a type of drug called a monoclonal antibody that acts to block the activities of IL-33 and may be effective at reducing the number of COPD exacerbations.
阿斯替戈利单抗 在 慢性阻塞性肺疾病-临床试验注册中心-ICH GCP
2021年8月31日 · 本研究将评估 astegolimab 与标准护理慢性阻塞性肺疾病 (COPD) 维持治疗相结合的疗效、安全性和药代动力学，用于既往或目前吸烟且有频繁加重史的 COPD 患者。
Astegolimab, an anti-ST2, in chronic obstructive pulmonary …
We aimed to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. Methods: COPD-ST2OP was a single-centre, randomised, double-blinded, placebo-controlled phase 2a trial in moderate-to-very severe COPD. Participants were randomly assigned (1:1) with a web-based system to received 490 mg ...
Clinical Trial – Chronic Obstructive Pulmonary Disease – Ef...
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a …
Astegolimab is a type of drug called a monoclonal antibody that may effectively reduce COPD exacerbations. Astegolimab is an experimental drug, which means health authorities have not approved it for treating COPD. In two previous clinical trials (called ‘parent’ trials or studies), people with COPD were given astegolimab or placebo (a